Skip to main
SMMT
SMMT logo

Summit Therapeutics (SMMT) Stock Forecast & Price Target

Summit Therapeutics (SMMT) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 53%
Buy 29%
Hold 12%
Sell 6%
Strong Sell 0%

Bulls say

Summit Therapeutics Inc. is positioning itself favorably in the biopharmaceutical sector, particularly with its CDI product candidate, ridinilazole, which has demonstrated a significant response rate among patients in the ongoing HARMONi trial, with 65% showing a PFS benefit. The anticipated positive results from ongoing Phase 3 trials, specifically for its NSCLC product, ivonescimab, are supported by an increased probability of success, which could lead to substantial market traction given the potential for peak annual sales surpassing $25 billion, akin to leading competitors. Furthermore, the company's projections for a meaningful improvement in overall survival (OS) metrics speak to its strong clinical pipeline and potential for long-term revenue growth in the highly competitive oncology market.

Bears say

Summit Therapeutics's stock faces significant challenges stemming from a low probability of success for its product candidate, Ivo, which is currently assessed at only 20% due to concerns about its clinical efficacy and potential safety signals emerging in Phase 3 studies. Additionally, a lack of differentiated clinical data and competition from newly approved drugs may severely hinder the sales potential of Summit's products, adversely impacting revenue forecasts. The company also confronts regulatory risks, clinical trial failures, and potential dilution, all of which contribute to a grim financial outlook and amplify investor uncertainty.

Summit Therapeutics (SMMT) has been analyzed by 17 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 29% recommend Buy, 12% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Summit Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Summit Therapeutics (SMMT) Forecast

Analysts have given Summit Therapeutics (SMMT) a Buy based on their latest research and market trends.

According to 17 analysts, Summit Therapeutics (SMMT) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Summit Therapeutics (SMMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.